By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Lipitor: How Pfizer Hopes to Slow the Decline
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > Lipitor: How Pfizer Hopes to Slow the Decline
Business

Lipitor: How Pfizer Hopes to Slow the Decline

DavidEWilliams
DavidEWilliams
Share
4 Min Read
SHARE

By all rights, Pfizer’s Lipitor revenues should drop like a stone once the drug loses US patent protection at the end of the month. And I think it’s likely that over time prescription Lipitor sales will whither away. Pfizer’s original plan was to replace Lipitor sales with those of torcetrapib, a new and improved drug that would sustain and expand the Pfizer franchise. That didn’t work out when the drug failed in late stage development.

By all rights, Pfizer’s Lipitor revenues should drop like a stone once the drug loses US patent protection at the end of the month. And I think it’s likely that over time prescription Lipitor sales will whither away. Pfizer’s original plan was to replace Lipitor sales with those of torcetrapib, a new and improved drug that would sustain and expand the Pfizer franchise. That didn’t work out when the drug failed in late stage development.

Now Pfizer is left with the tough task of defending Lipitor against cheaper, but theoretically identical, products. According to the Wall Street Journal (Forget Generics, Pfizer Has Plenty of ‘Lipitor for You’) the company is confident that it can succeed, at least to a reasonable degree.

Pfizer said Tuesday it is striking deals with drug-benefit plans and providing discounts to patients to encourage continued use of branded Lipitor, and to preserve a big chunk of its nearly $11 billion in annual sales.

More Read

America’s High Cost Healthcare Problem
Health Insurance “Rate Shock”: A New Opportunity Within the Broader Trend of Healthcare Consumerism
How to Shop for a Quality-Based Health Plan [video interview]
Pharmacist Must Have Apps – Great for MDs and Nurses Too
Anecdote-Driven Systems Engineering and Complaint-Based Interoperability Design Won’t Solve Health IT Woes

If Pfizer succeeds, it will only be because of the strange and somewhat dysfunctional structure of the health insurance market.

In general, health insurers seek to pay less rather than more for a drug. They do this with formularies, which discourage the use of pricey drugs through higher co-pays and prior authorization requirements. When a generic is available, there should always be a significant financial incentive for the patient to choose it rather than the branded product. However, Pfizer is likely to undermine this in a couple of ways:

  • By providing coupons or co-pay cards to patients, which cancel out the differential between the co-pay for Lipitor and the generic equivalent and effectively block health plans’ attempts to give patients “skin in the game”
  • Making rebate or market share incentive deals with pharmacy benefit managers (PBMs) to enable those companies to make significantly more margin from Lipitor than from the generic

These deals cut into Pfizer’s margins but preserve sales revenue, cost the patient nothing, and put money in the pockets of PBMs.

So who loses?

The main losers are whoever is paying health insurance premiums, i.e., employers and individuals. Everyone’s premium is higher than it could be to the extent that Pfizer is successful in its strategy. That’s because ultimately health plans end up paying more when Lipitor is used rather than a generic.

It’s worth noting that Massachusetts is the only state in the country that forbids the use of co-pay coupons by drug makers. I support that policy because it helps contain costs.

 

 

 


TAGGED:LipitorPfizerpharmaceuticals
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

a woman walking on the hallway
6 Easy Healthcare Ways to Sit Less and Move More Every Day
Health
September 9, 2025
Clinical Expertise
Healthcare at a Crossroads: Why Leadership Matters More Than Ever
Global Healthcare
September 9, 2025
travel nurse in north carolina
Balancing Speed and Scope: Choosing the Nursing Degree That Fits Your Goals
Nursing
September 1, 2025
intimacy
How to Keep Intimacy Comfortable as You Age
Relationship and Lifestyle Senior Care
September 1, 2025

You Might also Like

healthcare pricing
BusinessFinancePolicy & Law

Healthcare’s Pricing Cabal

February 21, 2013

Health Start-Ups! – What Makes a Great Startup Incubator?

June 18, 2013

Largest One-YearJump in Health Spending

March 3, 2011
Healthcare financing
BusinessFinance

How Hospitals can Obtain Financing in a Challenging Environment

May 11, 2016
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?